iShares MSCI Australia ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI Australia ETF trades at $28.65, while Medpace Holdings Inc trades at $538.6 (market cap $15.11B). Which is the better fit depends on your goals.
| EWA | MEDP | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $30.26 | $620.59 |
52-Week Low | $24.95 | $308.88 |
Market Cap | — | $15.11B |
Enterprise Value | — | $14.58B |
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.66, down 0.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $28, while resistance clusters near $29. The stock lacks disclosed financial ratios, and a dividend of $0.40 is scheduled for June 2026. Recent news highlights Australian economic factors and sector-specific developments influencing sentiment.
The outlook is mixed, with technical strength offset by limited fundamental visibility. Risks include reliance on Australian market conditions and macroeconomic headwinds. Investment appeal hinges on future financial disclosures and broader market trends.
Medpace (MEDP) trades at $534.85, down 0.25% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.31. Recent earnings have consistently beaten estimates, and cash flow is projected to improve in 2026. News highlights focus on CRO demand shifts and a class action lawsuit from June 2026.
Outlook remains mixed; strong earnings momentum and operational efficiency support upside, but high valuation and legal overhangs pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term appreciation potential amid balanced investor sentiment.
Trailing returns across standard periods
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →